Biomedical Engineering Reference
In-Depth Information
Chapter 8
Manipulation of Leukocytes Using
Therapeutic RNAi Delivered by Targeted
and Stabilized Nanoparticles
Dan Peer
Laboratory of Nanomedicine, Department of Cell Research and Immunology, and
Center for Nanoscience and Nanotechnology, George S Wise Faculty of Life Sciences,
Tel Aviv University, Tel Aviv 69978, Israel
peer@post.tau.ac.il
RNA interference (RNAi) has just made it through the pipeline to
clinical trials. More studies aiming to translate RNAi toward an ideal
therapeutic tool are speeding ahead. However, in order for RNAi to
serve as personalized therapeutics and be approved clinically, safe,
specific, potent and flexible strategies must be devised for efficient
delivery of RNAi payloads to specific cell types. Despite the immense
potential, exogenous systemically applied RNAi remains a challenge,
particularly the delivery to hematopoietic cells. This chapter
describes the current systemic RNAi delivery platforms targeted
to leukocytes, with a focus on the integrin-targeted and stabilized
nanoparticles (I-tsNPs) strategy, which uses leukocyte integrins for
the delivery of siRNAs exclusively to cells of the immune system.
Search WWH ::
Custom Search